Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Quest Diagnostics Incorporated (NYSE:DGX) stock soared to a 52-week high, reaching a price level of $165.58. This peak reflects a robust year for the healthcare diagnostics company, which has seen its shares climb significantly over the past year. With a market capitalization of $18.15 billion and a steady dividend yield of 1.93%, Quest has demonstrated strong financial stability. According to InvestingPro analysis, the company currently trades above its Fair Value, suggesting investors should monitor valuation metrics carefully. The ascent to the 52-week high underscores the market’s confidence in Quest Diagnostics’ growth trajectory and its ability to capitalize on the expanding demand for diagnostic services. The company has maintained a solid revenue growth of 2.6% and trades at a P/E ratio of 20.58. InvestingPro data reveals that management has been aggressively buying back shares, with 7 additional exclusive insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Quest Diagnostics reported an impressive Q4 performance, outperforming analyst expectations for both earnings and revenue. The company posted adjusted earnings per share of $2.23, surpassing the consensus estimate of $2.19, and revenue reached $2.62 billion, beating expectations of $2.58 billion and marking a 14.5% YoY increase. The recent developments also highlight Quest Diagnostics’ 14.5% revenue growth in Q4, driven in part by the completion of eight acquisitions in 2024, including LifeLabs in Canada. CEO Jim Davis expressed confidence in the company’s robust utilization and momentum from the 2024 acquisitions. Looking ahead, Quest Diagnostics anticipates revenue between $10.70 billion and $10.85 billion for full year 2025, representing 8.4% to 9.9% growth. Adjusted EPS is forecast at $9.55 to $9.80. Additionally, the company has raised its quarterly dividend by 6.7% to $0.80 per share.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.